John N. Lofblom

Stockholm, AB 10691, Sweden

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 109 publications

Correction: Trimerization of CD40L-specific affibody molecules using collagen domains enhances target binding and CD40 blockade.

Correction: Trimerization of CD40L-specific affibody molecules using collagen domains enhances target binding and CD40 blockade.

Journal: Cellular and molecular life sciences : CMLS
Published: August 10, 2026

Imaging of ROR1 expression in tumors using radiolabeled affibody molecules.

Imaging of ROR1 expression in tumors using radiolabeled affibody molecules.

Journal: European journal of nuclear medicine and molecular imaging
Published: June 08, 2026

Biparatopic affibody engineering enables high-affinity sortilin blockade and progranulin elevation.

Biparatopic affibody engineering enables high-affinity sortilin blockade and progranulin elevation.

Journal: New biotechnology
Published: February 26, 2026

Combining bacterial display and protein language models to engineer a CD69-binding affibody for molecular imaging of immune activation.

Combining bacterial display and protein language models to engineer a CD69-binding affibody for molecular imaging of immune activation.

Journal: Protein engineering, design & selection : PEDS
Published: February 18, 2026

Trimerization of CD40L-specific affibody molecules using collagen domains enhances target binding and CD40 blockade.

Trimerization of CD40L-specific affibody molecules using collagen domains enhances target binding and CD40 blockade.

Journal: Cellular and molecular life sciences : CMLS
Published: February 11, 2026

Trimerization of CD40L-specific affibody molecules using collagen domains enhances target binding and CD40 blockade.

Trimerization of CD40L-specific affibody molecules using collagen domains enhances target binding and CD40 blockade.

Journal: Cellular and molecular life sciences : CMLS
Published: February 11, 2026

Increased affinity by dimerization of radiolabeled Affibody molecule ATH001 targeting PDGFRβ.

Increased affinity by dimerization of radiolabeled Affibody molecule ATH001 targeting PDGFRβ.

Journal: EJNMMI radiopharmacy and chemistry
Published: January 15, 2026

Engineering a conditionally active cetuximab prodrug via affibody-based paratope masking.

Engineering a conditionally active cetuximab prodrug via affibody-based paratope masking.

Journal: Journal of biological engineering
Published: January 13, 2026

PDGFRß targeted positron emission tomography as a non-invasive biomarker for activated hepatic stellate cells: lasts steps before clinical translation.

PDGFRß targeted positron emission tomography as a non-invasive biomarker for activated hepatic stellate cells: lasts steps before clinical translation.

Journal: EJNMMI radiopharmacy and chemistry
Published: June 10, 2025

PET imaging of platelet derived growth factor receptor β in lung fibrosis.

PET imaging of platelet derived growth factor receptor β in lung fibrosis.

Journal: EJNMMI radiopharmacy and chemistry
Published: May 08, 2025

Engineering affibody domains as anti-idiotypic masks for nivolumab-based prodrugs.

Engineering affibody domains as anti-idiotypic masks for nivolumab-based prodrugs.

Journal: Protein engineering, design & selection : PEDS
Published: May 06, 2025

Affibody-based HER2 prodrug shows conditional cytotoxic effect on HER2-positive cancer cells.

Affibody-based HER2 prodrug shows conditional cytotoxic effect on HER2-positive cancer cells.

Journal: Biochemical and biophysical research communications
Published: March 14, 2025
Showing 1-12 of 109

Last Updated: 09/26/2026